Protective effect of natural rotavirus infection in an Indian birth cohort

New England Journal of Medicine

Volumn 365, Issue 4, 2011, Pages 337-346

  Gladstone, Beryl P ^a,b   Ramani, Sasirekha ^a   Mukhopadhya, Indrani ^a,d   Muliyil, Jayaprakash ^a   Sarkar, Rajiv ^a,c   Rehman, Andrea M ^g   Jaffar, Shabbar ^g   Gomara, Miren Iturriza ^h   Gray, James J ^e,h   Brown, David W G ^h   Desselberger, Ulrich ^f   Crawford, Sue E ^c   John, Jacob ^a   Babji, Sudhir ^a   Estes, Mary K ^c   Kang, Gagandeep ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b UNIVERSITY OF FREIBURG   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; ROTAVIRUS VACCINE;

AGE; ANTIBODY BLOOD LEVEL; ARTICLE; ASYMPTOMATIC INFECTION; CHILD; COHORT ANALYSIS; DIARRHEA; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; INCIDENCE; INDIAN; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; NATURAL ROTAVIRUS INFECTION; NUTRITIONAL STATUS; PRESCHOOL CHILD; PRIORITY JOURNAL; REINFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAVIRUS INFECTION; SCORING SYSTEM; SEROCONVERSION; URBAN AREA; VESIKARI SCORE; VIRAL GASTROENTERITIS; VIRUS STRAIN;

EID: 79960849653     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1006261     Document Type: Article

References (33)

1. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009;200:Suppl 1:S9-S15.
2. Linhares AC, Velázquez FR, Pérez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008;371:1181-9. (Pubitemid 351458523)
3. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. (Pubitemid 43048947)
4. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. (Pubitemid 43048948)
5. Meeting of the Immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Wkly Epidemiol Rec 2009;84:220-36.
6. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362:289-98.
7. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8. (Pubitemid 26338732)
8. Fischer TK, Valentiner-Branth P, Steinsland H, et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis 2002;186:593-7. (Pubitemid 34925530)
9. O'Ryan ML, Hermosilla G, Osorio G. Rotavirus vaccines for the developing world. Curr Opin Infect Dis 2009;22:483-9.
10. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009;301:2243-51.
11. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;376:615-23.
12. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010;376:606-14.
13. John TJ. Problems with oral poliovaccine in India. Indian Pediatr 1972;9:252-6.
14. John TJ, Jayabal P. Oral polio vaccination of children in the tropics: the poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972;96:263-9.
15. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000;18:2399-410. (Pubitemid 30156811)
16. Gladstone BP, Das AR, Rehman AM, et al. Burden of illness in the first 3 years of life in an Indian slum. J Trop Pediatr 2010;56:221-6.
17. Gladstone BP, Muliyil JP, Jaffar S, et al. Infant morbidity in an Indian slum birth cohort. Arch Dis Child 2008;93:479-84. (Pubitemid 352025764)
18. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990;162:1055-62. (Pubitemid 20353583)
19. Velázquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000;182:1602-9.
20. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990;22:259-67.
21. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503. (Pubitemid 20078123)
22. Gentsch JR, Glass RI, Woods P, et al. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 1992;30:1365-73.
23. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990;28:276-82. (Pubitemid 20050935)
24. Iturriza-Gómara M, Kang G, Gray J. Rotavirus genotyping: keeping up with an evolving population of human rotaviruses. J Clin Virol 2004;31:259-65. (Pubitemid 39371057)
25. Ward RL, Bernstein DI, Smith VE, et al. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis 2004;189:2290-3. (Pubitemid 38757202)
26. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York: John Wiley, 1999.
27. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 1991;164:277-83.
28. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993;168:282-7. (Pubitemid 23210600)
29. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection - a prospective longitudinal study in young children. N Engl J Med 1983;309:72-6. (Pubitemid 13063589)
30. Georges-Courbot MC, Monges J, Beraud-Cassel AM, Gouandjika I, Georges AJ. Prospective longitudinal study of rotavirus infections in children from birth to two years of age in Central Africa. Ann Inst Pasteur Virol 1988;139:421-8. (Pubitemid 19024040)
31. Reves RR, Hossain MM, Midthun K, et al. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children: calculation of risk for second episodes using age-specific person-years of observation. Am J Epidemiol 1989;130:981-8. (Pubitemid 19285336)
32. Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. J Infect Dis 1994;169:900-4. (Pubitemid 24102131)
33. Banerjee I, Gladstone BP, Le Fevre AM, et al. Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis 2007;195:625-32.